2025.01.09
On December 16, 2024, Nona Biosciences (Suzhou) Co., Ltd. ("Nona Biosciences"), a wholly-owned subsidiary of HBM Holdings Limited (stock code: 02142.HK), announced a research collaboration m88 bonus license agreement to discover next-generation T-cell engagers (“TCEs”) with Cm88 bonusid Therapeutics, Inc. ("Cm88 bonusid").
Under the terms of the agreement, Nona Biosciences is eligible to receive up to USD 320 million, including an upfront payment m88 bonus potential milestone payments. Cm88 bonusid will be responsible for all further product development.
m88 bonus was engaged by Nona Biosciences to review and revise the agreement. With its consistent delivery of efficient and rigorous legal services and detail-oriented and professional expertise, m88 bonus’s team was recognized and trusted by the client.
Partnerm88 sport bettingled the m88 bonus team.
